Form 603, “Notice of initial substantial holder” was lodged with the Australian Securities Exchange on 30th January at 5:25 PM.
View the Form 603.
Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway
September 9, 2025
Highlights Dr Nina Webster appointed as IBX Non-Executive Director, bringing significant clinical development expertise and corporate experienceto the IBX Board ahead of HER2 Breast cancer